Search Results - "Glanzman, R"

Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials by Backonja, Miroslav, Glanzman, Robert L

“…Background: Pain is one of the most common reasons for seeking medical attention, and neuropathic pain is among the most common types of pain. Despite its…”
Get full text

Proof of concept studies for tissue-protective agents in multiple sclerosis by Mehta, LR, Schwid, SR, Arnold, DL, Cutter, GR, Aradhye, S, Balcer, LJ, Calabresi, PA, Cohen, JA, Cole, PE, Glanzman, R, Goelz, S, Inglese, M, Kapoor, R, Kappos, L, Kreitman, R, Lublin, FD, Mann, A, Marrie, RA, O'Looney, P, Polman, CH, Ravina, BM, Reingold, SC, Richert, JR, Sandrock, AW, Waubant, E

“…Background There is considerable interest in tissue-protective treatments for multiple sclerosis (MS). Methods and Objectives We convened a group of MS…”
Get full text

Association Between Monthly Joint Replacement Volume and Patient Outcomes by Johnson, TJ, Skowron, P, Winn, T, Hohmann, SF, Glanzman, R

“…OBJECTIVES: Reducing variations in outcomes for total hip arthroplasty (THA) and total knee arthroplasty (TKA) procedures will be critical for providing…”
Get full text

PHS11 - Association Between Monthly Joint Replacement Volume and Patient Outcomes by Johnson, TJ, Skowron, P, Winn, T, Hohmann, SF, Glanzman, R

Get full text

Improvements in the Power of Detecting Treatment Effect in a Primary Progressive Multiple Sclerosis (PPMS) Clinical Trial with the Use of Composite Disability Outcome Endpoints (P01.151) by Zhang, J., Waubant, E., Cutter, G., Wolinsky, J., Glanzman, R.

“…Abstract only…”
Get full text

Brachial plexopathy after botulinum toxin injections by Glanzman, R L, Gelb, D J, Drury, I, Bromberg, M B, Truong, D D

Get full text

Use of gabapentin for postherpetic neuralgia: Results of two randomized, placebo-controlled studies by Stacey, Brett R., Glanzman, Robert L.

“…Background: Postherpetic neuralgia (PHN), which affects up to 70% of elderly persons with herpes zoster, can have debilitating effects, including physical and…”
Get full text

Long-Term Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Week 96 Results of a Phase II, Randomized, Multicenter Trial (S30.006) by Hauser, S., Kappos, L., Li, D., Calabresi, P., O'Connor, P., Bar-Or, A., Barkhof, F., Wells, C., Leppert, D., Glanzman, R., Tinbergen, J.

“…Abstract only…”
Get full text

PND1 ASSESSING THE NET CLINICAL BENEFIT AND ABSOLUTE RISK REDUCTION OF DISEASE MODIFYING DRUGS IN RELAPSING REMITTING MULTIPLE SCLEROSIS by AL-Sabbagh, A, Bennett, R, Glanzman, R

Get full text

Platelet heparin-neutralizing factor (platelet factor 4) by Lüscher, E F, Käser-Glanzman, R

“…The heparin-neutralizing platelet factor (PF4) is released from platelets under the influence of inducers of aggregation and nucleotide-release in the form of…”
Get more information